Mutation Quirk In NRx’s COVID-19 Vaccine Asset Could Help Fight VOCs
Executive Summary
The firm’s live-virus COVID-19 vaccine candidate BriLife is entering a late-stage study following Phase II success, sparking hopes that its spontaneous mutations could parallel those of VOCs.
You may also be interested in...
NRx’s COVID-19 Vaccine Candidate BriLife Impresses In Phase II
NRx’s BriLife has demonstrated strong potential in early data from a mid-stage COVID-19 trial, spurring the company on to begin a Phase IIb/III study as soon as possible.
Apellis Bounces Back After Needle Discontinuation Amid Syfovre Safety Concerns
Real-world cases of retinal vasculitis linked with Syfovre for geographic atrophy in age-related macular degeneration may have resulted from a material used in a specific filter needle, the US firm revealed, as analysts remained optimistic on the product.